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ABSTRACT  
Melanoma incidence is rising rapidly worldwide among white skinned populations.  Earlier 
diagnosis is the principal factor that can improve prognosis. Defining high-risk populations 
using risk prediction models may help targeted screening and early detection approaches.  In 
this systematic review we searched Medline, EMBASE and the Cochrane Library for primary 
research studies reporting or validating models to predict risk of developing cutaneous 
melanoma.  4141 papers were identified from the literature search and six through citation 
searching.  25 risk models were included.  Between them, the models considered 144 possible 
risk factors, including 18 measures of number of naevi and 26 of sun/UV exposure.   Those 
most frequently included in final risk models were number of naevi, presence of freckles, 
history of sunburn, hair colour and skin colour.  Despite the different factors included and 
different cut-offs for sensitivity and specificity, almost all models yielded sensitivities and 
specificities that fit along a summary ROC with AUROC of 0.755, suggesting most models 
had similar discrimination.  Only 2 models have been validated in separate populations and 
both also showed good discrimination with AUROC values of 0.79 (0.70-0.86) and 0.70 
(0.64-0.77).  Further research should focus on validating existing models rather than 
developing new ones.   
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INTRODUCTION 
Melanoma is one of the fastest growing cancers worldwide: age adjusted incidence 
rates have been increasing in most of the fair-skinned populations in recent decades; and 
160000 new cases are diagnosed annually worldwide (1–5).  As earlier diagnosis is the 
principal factor that can improve the prognosis of patients with melanoma (6), there is 
considerable interest in the development of screening programmes. The SCREEN project in 
northern Germany suggested that population screening may have a substantial impact on  
melanoma incidence and 5 year mortality (7, 8) leading to the implementation of a national 
statutory skin cancer early detection program in Germany in 2008. However, such mass 
screening is not currently recommended by the US Preventive Services Task Force (9) or in 
other countries.  Modelling studies suggest that selective, targeted screening might be a more 
cost-effective strategy (10, 11). Such a stratified approach is currently recommended by the 
Royal Australian College of General Practitioners. Australian primary care physicians are 
advised to perform skin examinations every 3-12 months in people with multiple atypical or 
dysplastic naevi and a history of melanoma or a first-degree relative with melanoma (12). 
This approach is also being considered by the Department of Health in the United Kingdom.  
 
The aims of such targeted screening programs are to identify people at higher risk of 
melanoma and to offer them preventive advice about sun protection and skin awareness and 
early consultation or surveillance (13–15). The identification of people at higher risk may be 
improved by the use of risk prediction models.  Several risk models have been developed but 
their strengths, weaknesses and relative performance are uncertain. We report a systematic 
review and comparison of risk prediction models for melanoma.  
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MATERIALS AND METHODS 
Search strategy 
An electronic literature search of Medline, EMBASE and the Cochrane Library up to 
August 2013 was performed using a combination of subject headings and free text 
incorporating ‘melanoma’, ‘risk/risk factor/risk assessment/chance’ and 
‘prediction/model/score’ (see Supplementary File 1 for complete search strategy).  We then 
manually screened the reference lists of all included papers. 
 
Study selection 
Studies were included if they fulfilled all of the following criteria: (i) are published as 
a primary research paper in a peer-reviewed journal; (ii) identify risk factors for developing 
melanoma at the level of the individual; (iii) provide a measure of relative or absolute risk 
using a combination of risk factors that allows identification of people at higher risk of 
melanoma; (iv) use a statistical method to develop the final risk model; and (iv) are 
applicable to the general population.  As the focus of the review is to summarise the risk 
prediction models for incident melanoma, studies developing models for the risk of 
recurrence and prognostic models were excluded.  Studies including only highly selected 
groups, for example immunosuppressed patients or those with a previous history of cancer, 
and conference proceedings were also excluded.  The decision to only include papers which 
use a statistical method to develop the final risk model was made to differentiate between 
those studies which had set out to develop a risk model, using either a step-wise method or 
maximisation of sensitivity and specificity to select the variables for the final model, from the 
large number of variable-finding studies which provide tables with odds ratios or risk ratios 
adjusted simultaneously for all considered variables but do not attempt to generate or test a 
risk model.   
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One reviewer (JUS) performed the search and screened the titles and abstracts to 
exclude papers that were clearly not relevant.  A second reviewer (FW) independently 
assessed a random selection of 5% of the papers excluded at that stage.  For papers where a 
definite decision to reject could not be made based on title and abstract alone, the full-text 
was examined.  At least two reviewers (JUS and FW/JE/AK) independently assessed all full-
text papers, and those deemed not to meet inclusion criteria by both researchers were 
excluded.  Papers for which it was unclear whether or not the inclusion criteria were met 
were discussed at consensus meetings including all researchers. Papers written in languages 
other than English were translated into English for assessment and subsequent data 
extraction.  
 
Data extraction and synthesis 
Data were extracted independently by at least two researchers (JUS and FW/JE/AK) 
using a standardised form to minimise bias. The form included details on: (i) the development 
of the model, including the study design, selection of participants, the variables considered 
for inclusion in the model and how they were selected; (ii) the risk model itself, including the 
variables included, the method of administration and whether it requires physician input or 
population training; (iii) the performance of the risk model in the development population, 
including measures of discrimination, accuracy, calibration and utility; and (iv) validation 
studies of the risk model and data collection tool, including the study design and performance 
of the risk model. 
For studies which reported the step-wise performance of models, only the model with 
the best performance was included.  For studies which included multiple different models, for 
example separate models for men and women or for self-assessment and physician 
assessment, all were included separately.  One paper (16) reported models for two different 
on June 22, 2014. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 3, 2014; DOI: 10.1158/1055-9965.EPI-14-0295 
6 
 
age groups in additional to the cohort as a whole.  In this case only the model for the entire 
cohort was included.  
During the data extraction, risk factors were grouped into the following categories: 
personal characteristics; genetic factors; female hormonal factors; access to specialist skin 
care; personal medical history; family history; hair colour; eye colour; skin type (Fitzpatrick); 
skin colour, skin response to sun; history of sunburn; use of sun protection; number of naevi; 
number of atypical or dysplastic naevi; freckles; congenital naevi; other skin findings; new or 
changing naevi; sun/UV exposure (including sun bed use); and UV skin damage.  Separate 
categories were included for skin colour, skin response to the sun, and skin type (Fitzpatrick), 
which includes both skin colour and skin response to the sun (17). If papers used the term 
‘skin type’ but then defined that by the skin response to the sun this was extracted under skin 
response to the sun.      
Information concerning whether the risk models required physician input or could be 
performed without involvement of a healthcare professional was also extracted.  Risk models 
were classified as requiring physician input if they included any of the following factors: 
dysplastic or atypical naevi; actinic lentigines; total body naevus count; genetic analysis 
requiring samples; or specialised equipment such as dermoscopy or colorimetry. Naevus 
density, as in Marrett et al 1992 (18), was not considered to require physician input as 
participants were provided with images representing a range of naevus density and counting 
of individual naevi was not required.  
Reported measures of discrimination, accuracy, calibration and utility were used to 
compare the performance of risk models. The sensitivity and specificity of different models 
was also compared graphically by plotting a summary ROC curve using the Moses-
Littenberg method (19, 20) in RevMan version 5.2 and the summary AUROC calculated in 
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Meta-DiSc version 1.4  using Moses’ constant for linear models to fit the summary ROC 
curve.  
 
RESULTS 
After duplicates were removed, the search identified 4141 papers.  4080 of these were 
excluded at title and abstract level.  A further 42 were excluded after full-text assessment by 
at least two authors (JUS and FW/JE/AK).  There was complete agreement amongst 
researchers throughout the screening process and the most common reasons for exclusion 
were that the papers did not use a statistical method to develop the final risk model, were 
conference abstracts or not primary research.  Two well cited models, excluded because they 
were not developed using a statistical method, are those by Mar (21) and Glanz (22).  Mar et 
al 2011 selected risk factors and estimated relative risks for risk factor combinations from 
existing large meta-analyses (23–25) and data from the Victorian Cancer Registry. Glanz 
developed the BRAT (Brief skin cancer Risk Assessment Tool) through critically reviewing 
published literature on risk factors and their self-assessment and then piloted the 
questionnaire on a convenience sample of people at varying levels of risk to estimate the 
range of scores and test-retest reliability of the tool.  Neither tested the performance of the 
models in any populations with melanoma.  
Six further papers were identified through citation searching giving 25 papers for 
inclusion.  Of these, four provided validation of other models and four included more than 
one risk model.  This review, therefore, describes 25 risk prediction models (Figure 1).   
A summary of these 25 models, along with measures of performance in the 
development population and notable strengths and weaknesses, are given in Table 1.  Fifteen 
require physician input whilst 10 can be performed by self-assessment. Discriminatory 
performance was provided for fourteen.  Most had values for the area under the receiver 
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operating curve (AUROC) between 0.7-0.8 with little difference between those suitable for 
self-assessment and those requiring a health care professional.  Poorer discrimination was 
seen in those models including only skin colour and skin type (0.54) (26), age, sex, cutaneous 
melanin and genotyping (0.65) (27) and in the only model developed in a cohort study to 
provide a measure of performance (0.62) (28). The highest discrimination was for a model 
including a suspicious melanoncytic lesion on dermoscopy (0.86) (29) with a second model 
developed from a small case control study in Brazil where there were more cases than 
controls also reporting high discrimination (0.85) (30).  
A measure of accuracy was provided in ten studies.  The sensitivity and specificity 
varied between them but a summary ROC curve (Figure 2) shows that they all lie very close 
to the curve. This shows that despite all the heterogeneity in model development and risk 
factors, there is very little heterogeneity in the predictive ability of the models with the 
variation in sensitivity and specificity likely a reflection of the cut offs chosen in different 
studies. The AUROC of this summary curve is 0.755. 
Only three models had reported measures of calibration (28, 29, 31).  All three 
showed good calibration but all had been tested in the development population where 
calibration would be expected to be high. 
Further details of the development of each model are given in Supplementary Tables 
S1 and S2 for case-control and cohort studies respectively.  Twenty-one were case-control 
studies and 4 cohort studies.  Overall the reporting of the studies was variable.  Of the 21 
case-control studies, the method of selecting the variables for consideration was given in only 
11, of which for 8 the method was a literature review, and the predictor variables and 
outcomes were evaluated in a blinded fashion in only 4.  Cases were selected from either 
cancer registries or dermatology clinics and all required histological confirmation of 
diagnosis.  Controls were selected from hospital clinics in 7 studies, the general population in 
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5, dermatology clinics in 4 and primary care in 3.  Most controls were matched by age and 
gender with a mean age of 43-57 years.  Of the 4 cohort studies, only Neilsen et al 2011 (16) 
provided any detail of the method of selecting the variables, none were evaluated in a blinded 
fashion and Goldberg 2007 (32) did not require a histological diagnosis. Neilsen et al 2011 
(16) included only female participants with Cho et al 2005 (28) also heavily female 
dominated.  
Table 2 shows additional details of those models in which either the model itself or 
the method of data collection used for the model has been validated or in which efficiency 
has been estimated.  Only one model, Fortes et al 2010 (33), has been validated in an external 
population and one, Williams et al 2011 (34), in a separate sub-group of the original study 
population.  English et al (35) also divided their initial study population into two but they 
used the second sub-population to further refine the model developed in the first sub-
population rather than validate the performance of the model in a separate population.  
Between them, the 25 risk prediction models considered 144 different possible risk 
factors (Supplementary Table S3).  These included 18 different measures of number of naevi, 
26 of sun / UV exposure and 14 of history of sunburn.  There were also multiple definitions 
of dysplastic naevi with each research group using a different definition.  Categorising the 
different risk factors, as shown in Supplementary Table S3, allowed comparison of those 
considered and included in each of the risk models (Table 3).  This shows that the risk factors 
most frequently included in the models are (in order of frequency) number of naevi, freckles, 
hair colour, skin colour, history of sunburn and sun/UV exposure.  The risk factors most 
likely to remain in the final model after consideration are age, number of naevi, skin type, 
skin colour, personal history of skin cancer and freckles.  Ethnicity, other personal 
characteristics such as socio-demographic measures, female hormonal factors, use of sun 
protection and congenital naevi were not included in any of the final models and a family 
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history of skin cancer and eye colour were included in the final model in less than one in five 
times they were considered.    
 
DISCUSSION 
Principal findings 
This is the first systematic review of risk prediction models for melanoma. It shows 
that multiple risk models exist and that they have the potential to identify individuals at 
higher risk of melanoma.  Comparisons between the different models are difficult due to the 
lack of validation studies and heterogeneity in choice and definition of variables.  Despite 
this, however, we show that most include well established risk factors and the AUROC of a 
summary ROC curve is comparable with those for other cancers, such as breast cancer 
(0.716-0.762) (36) and colon cancer (0.61-0.74) (37). There was also little difference in 
model performance between those scores suitable for self-assessment and those requiring a 
health care professional, suggesting potential for use at a population level to identify people 
at higher risk of melanoma.   
 
Strengths and limitations 
The main strengths of this review are the use of broad inclusion criteria and the 
systematic search of multiple databases not limited by language.  This approach enabled us to 
identify published risk models even when developing the risk model had not been the primary 
aim of the study, and in doing so reduces the risk of selection bias.  Whilst we cannot exclude 
publication bias we also expect this to be minimal because of the exploratory nature of many 
of the studies and the absence of performance data.   
As with most systematic reviews, the main limitation is the quality of the published 
data.  Notably, in this review it was difficult to perform direct comparisons of the risk models 
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due to the lack of validation studies for most of the risk models.  The majority of studies also 
gave no indication of how the authors decided which risk factors to consider for inclusion in 
the model and 144 different risk factors were considered with varying definitions.  
Additionally, many of the risk factors are subjective in nature and subject to recall bias, 
which is likely to overestimate the performance of those models developed from case control 
studies, and only 4 included blinding of the investigator to melanoma status.  By presenting 
all the risk models together for the first time, however, we are able to demonstrate this 
heterogeneity whilst making comparisons where possible.  
 
Evaluation of the risk models  
The 25 risk models differ in the risk factors included, the method of administration 
and their performance.  Most contain established risk factors for melanoma, however, there 
was considerable variation amongst the definitions and measures used.  In some cases, 
notably history of sunburn and sun / UV exposure, this likely reflects the difficulty measuring 
exposure to the risk factor, both due to its subjective nature and the need to recall events in 
the past.  This is in contrast to more objective and consistent measures, such as eye colour, 
skin type or hair colour for which many fewer variations were seen.  In other cases, 
particularly number of naevi and atypical and dysplastic naevi, the range of definitions 
probably reflects on-going uncertainty within the literature and the controversy around a non-
histological diagnosis of an atypical or dysplastic naevus (38). In all cases, however, it 
demonstrates the large number of variables in use within the field.  Whilst it is unlikely that a 
single measure of each risk factor will be appropriate for all situations, increased consistency 
would allow more meaningful comparisons in future research. 
With such a large number of risk factors considered it is perhaps not surprising that 
the models differ widely in the risk factors included.  Most include a measure of number of 
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naevi and skin type or colour and either include or adjust for age and gender but beyond that 
it is difficult to make generalisations.   
Performance measures were only available for 16 models in the development 
population and two in external populations.  Despite the variations already described, 
however, the accuracy, measured by the sensitivity and specificity, is consistent across them.  
By virtue of the cut-offs set by the authors, some have higher specificity and lower sensitivity 
(18, 34, 35, 39) whilst others have higher sensitivity and lower specificity (26, 31, 33).  The 
summary ROC curve, however, shows that, despite including a range of different variables, 
there is very little heterogeneity in the predictive ability of the models with the variations in 
sensitivity and specificity reflecting different cut-offs. One reason for this may be that there is 
a group of core risk factors responsible for most of the increased risk.  Due to the range of 
factors included in the different models, however, it is not possible to identify those from the 
available studies.   
The discrimination of the models, as measured by the area under receiver operating 
curve, compares favourably with risk models used for other cancers, including breast cancer 
with AUROCs of 0.716-0.762 (36) and colon cancer with AUROCs of 0.61-0.74 (37).  Care 
must be taken when making such comparisons, however, as many of these have been 
developed and validated in large cohort studies whilst the majority of melanoma risk models 
have been developed from case-control studies with up to 60% prevalence of melanoma 
which will inflate their performance through spectrum bias. 
 
Evaluation of individual risk factors 
Whilst evaluation of individual melanoma risk factors was not the primary aim of this 
study, by including only studies that used a statistical method to develop a risk model and 
extracting the number of times a risk factor was included in the final model when it was 
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considered, the results of our analysis confirm the importance of several established risk 
factors for melanoma (23–25).   These include age, number of naevi, skin type and colour, 
personal history of melanoma or non-melanocytic skin cancer, freckles, dysplastic naevi and 
hair colour.  Sun exposure, history of sunburn and skin response to the sun were also included 
in many of the final models but only half the times they were considered (53, 50 and 47% 
respectively), perhaps reflecting their subjective nature and risk of recall bias.  Eye colour 
was also only included in 4 of the 13 models in which it was considered and this is likely to 
be due to known correlation between hair colour, eye colour, freckles and skin colour (23).   
An unexpected finding was the absence of family history in many of the models.  It 
was considered in 18 of the models but only remained in the final score in 6.  This differs 
from earlier studies in which approximately 10% of cases of melanoma have reported 
heredity (23, 40). It may be that other phenotypic markers which remain in the risk model are 
strongly correlated with family history or may simply reflect the very low incidence of true 
familial melanoma in the melanoma population.  Some other risk factors, including for 
example genetic factors, ethnicity and female hormone factors, were also not considered by 
very many of the models and so their potential importance may be underestimated.   
 
Implications for clinicians and policy makers 
This review shows that multiple risk models for prediction of the development of 
melanoma exist and that they have the potential to identify individuals at higher risk of 
melanoma.  Clinicians will be interested to see the range and relative performance of 
different risk models.  However, all the risk scores were developed to predict risk of future 
disease rather than undiagnosed prevalent disease. Consequently, the results of this review 
will be of particular relevance to policy makers interested in the potential for using risk 
scores among asymptomatic people to identify a subset of the population for whom targeted 
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screening, surveillance or educational programmes could be offered to reduce the morbidity 
and mortality from melanoma.   
As English and Armstrong (35) point out, if a screening programme is to be directed 
towards a high risk group and is to have an impact on the disease as a whole, three criteria 
must be satisfied in addition to those for all screening programmes (41): People at high risk 
of the disease must be readily identifiable; those identified as being at high risk must form a 
large proportion of all patients who develop the disease; and this proportion must be 
substantially larger than the proportion of the whole population that constitutes the group at 
high risk. When assessed against these three criteria this review confirms that risk models 
exist which could be used to identify a group at higher risk of melanoma. Firstly, a number of 
risk models exist for which patient self-assessment is feasible and so they could be 
undertaken in clinical waiting rooms or via on-line platforms (16, 18, 28, 30–32, 34, 35, 39). 
Secondly, those models that provide values for sensitivity and specificity suggest that 
screening could identify a high risk group containing between 25-89% of people expected to 
develop melanoma and, thirdly, that this high risk group would comprise between 10-55% of 
the population.  These ranges are wide due to the variation in cut-offs selected in each study 
and reflects the trade-off between sensitivity and specificity.  For example, from the summary 
ROC, choosing a risk score with a specificity of 50% when 50% of the population would be 
classified as higher risk, sensitivity is around 80% so 80% of melanomas would be detected 
in that higher risk group. Choosing instead a score with a specificity of 80% when 20% 
would identified as high risk, the sensitivity falls to around 50% so only 50% of cases would 
be detected.    
Some, including Fortes (33), believe that as melanoma can be a fatal disease but 
referral to a dermatologist and excision or biopsy is relatively benign, it is better to give 
priority to sensitivity over specificity as the inclusion of false-positive cases may be less 
on June 22, 2014. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 3, 2014; DOI: 10.1158/1055-9965.EPI-14-0295 
15 
 
detrimental than false-negatives.  However, the utility of a risk score that identifies 50% of 
the population as higher risk is limited and any screening of asymptomatic people has 
considerable implications in terms of health care costs and both physical and psychological 
consequences.  Several previous studies have estimated the cost-effectiveness of various 
melanoma screening strategies.  One-off screening of a white population of all ages at 
average risk by a dermatologist has been shown to cost $172,276 per year-of-life-saved 
(YLS) (42) but this cost falls dramatically when screening is targeted to higher risk 
populations, defined variously by age, family history or phenotypic characteristics (10, 11, 
43). Whilst a full economic analysis is beyond the scope of this review, the risk scores 
described are able to identify higher risk groups with greater discriminatory ability and 
accuracy than age, family history or phenotypic characteristics alone, and so any screening 
programme based on one of the risk models is likely to be even more cost-effective.  
 
Implications for future research 
The finding that many of the models have similar performance characteristics despite the 
wide range of different variables included suggests that developing further models based on 
current known risk factors is unlikely to benefit the field.  As advances are made into genes 
that play a role in the susceptibility of melanoma (44, 45), development of new risk models 
incorporating genetic information may improve the discriminatory ability.  Until then, further 
research should focus on validating existing models in different populations and assessing the 
costs, feasibility, acceptability and adverse consequences of applying these models. 
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FIGURE LEGENDS 
Figure 1. PRISMA Flow Diagram 
Figure 2. Summary ROC curve for the ten models that provide values for sensitivity and 
specificity. Each data point represents the sensitivity and specificity for a single threshold of 
a risk model with horizontal and vertical bars indicating 95% confidence intervals. The 
AUROC of this summary curve is 0.755. 
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Table 1. Summary of risk prediction models 
  Components of score Model performance in development population General comments 
Author Factors included in score 
Physician 
input? 
Discrimination Calibration Accuracy Strengths Limitations 
Augustsson 
1991 (46) 
Skin type, hair colour, eye colour, total body 
naevus ≥ 2mm count, number of dysplastic 
naevi 
Yes      1)  Reproducible as relies on 
observation rather than recall 
1) Developed from survivors of 
melanoma so may be biased 
towards less poor outcomes and 
lower stages  
2) Only applicable to people 30-50 
years of age 
Bakos  
2013 (30) 
Hair colour; presence of freckles; sunburns in 
all life; skin colour; eye colour 
No AUROC 0.85 
(0.77-0.91) 
    1) Good discrimination 1) Developed from population with 
limited range of skin phototypes 
Barbini 
1998 (26) 
Skin colour using colorimeter and skin type Yes AUROC 0.54   Sens 86; Spec 45  
PPV 0.3; NPV 0.92 
  1) Very complicated to calculate  
2) Poor discrimination with two 
thirds of subjects misclassified as 
high risk 
Cho  
2005 (28) 
Gender; age; family history of melanoma; 
history of severe sunburn; number of naevi > 
3mm on arms or lower legs; hair colour 
No AUROC 0.62 
(0.58-0.65) 
Chi2 
goodness-of-
fit 9.28;  
p = 0.41 
  1) Based on large cohort study 
with 16 years follow-up 
1) Based on predominantly female 
white health professionals only;  
2) Would require a computer or 
expert to calculate risk using 
regression coefficients 
Dwyer 
2004 (27) 
Age; sex; cutaneous melanin; MC1R 
genotype 
Yes AUROC 0.65       1)Requires DNA sample;  
2) Only obtained genetic 
information from  67% of 
participants 
English 
1988 (35) 
Number of raised naevi on the arms; age on 
arrival in Australia; history of non-
melanocytic skin cancer; mean time spent 
outdoors in summer from the age of 10 to 
24; family history of melanoma 
No    Sens 54; Spec 84 1) High specificity 
2) Initially developed in 400 case 
control pairs then refined in 
separate 111 pairs 
3) Developed from large study 
with population based controls 
1) One variable not transferable 
outside Australia and number of 
hours spent outdoors difficult to 
estimate 
Fears  
2006  
(men)  (47) 
Skin colour; number of moles < 5mm; 
freckling; number of moles ≥ 5mm; severe 
solar skin damage 
Yes AUROC 0.7-0.8 
(a) 
    1) Simple and quick with only 2 
questions and examination of 
back  
1) Not applicable to people with 
prior melanoma or non-melanoma 
skin cancer or 1st degree relative 
with melanoma 
Fears  
2006 
(women) 
(47) 
Skin colour; number of  moles < 5mm; 
freckling; tanning ability; number of moles ≥ 
5mm; severe solar skin damage 
Yes AUROC 0.7-0.8 
(a) 
    1) Simple and quick with only 2 
questions and examination of 
back 
1) Not applicable to people with 
prior melanoma or non-melanoma 
skin cancer or 1st degree relative 
with melanoma 
Fortes 
2010 (33) 
Hair colour; skin type; presence of freckles; 
number of common naevi on the whole 
body; sunburn as a child 
Yes AUROC 0.79 
(0.75-0.82) 
  Risk cut off ≥ 3:  
Sens 88.6; Spec 
51.4** 
1) Externally validated  
2) Good discrimination and high 
sensitivity 
1) Developed from study with 
hospital based controls 
2) Potential for recall bias with 
sunburn as a child 
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  Components of score Model performance in development population General comments 
Author Factors included in score 
Physician 
input? 
Discrimination Calibration Accuracy Strengths Weaknesses 
Garbe  
1989 (48) 
Total number of naevi ≥ 2mm, total number 
of atypical naevi, actinic lentigines, 
occupational sun exposure and skin response 
to sun 
Yes        1)  Requires physician whole body 
examination by dermatologist so 
not feasible for primary care 
Garbe  
1994 (49) 
Number of naevi ≥ 2mm; presence of actinic 
lentigines; number of atypical melanocytic 
naevi; skin type; growth of any existing 
melanocytic naevi, hair colour 
Yes      1) Reproducible as relies on 
observation rather than recall 
1) Hospital based controls from 
dermatology department;  
2) Requires physician whole body 
examination by dermatologist so 
not feasible for primary care 
Goldberg 
2007 (32) 
History of previous melanoma, age over 50, 
does not see regular dermatologist, changing 
mole, gender 
No     1) Reproducible as relies on 
observation rather than recall 
1) Based on study with no follow 
up of patients and no histological 
diagnosis; 
2) Risk of bias as developed from 
self-selected population 
 2) Questionable relevance of 
absent dermatologist outside USA 
Guther 
2011 (29) 
Age; hair colour; past history of melanoma; 
suspicious melanocytic lesion on 
dermatoscopy 
Yes AUROC 0.86 Chi2 
Likelihood 
ratio  
p < 0.0001 
Sens 92.3 1) High discrimination and 
calibration;  
2)  Reproducible as relies on 
observation rather than recall 
1) Requires dermatoscopic 
examination  
2) Risk of bias as developed from 
self-selected population attending 
dermatologist 
Harbauer 
2003 
(physician 
assessment) 
(39) 
Skin type; UV damage to skin; number of 
naevi 
Yes AUROC 0.77 
(0.73-0.83) 
  Sens 42 (95% CI 33-
52); Spec 90 
1) Simple  
2) Good discrimination 
1) Would require a computer to 
implement risk model;  
2) Unclear how UV score was 
calculated 
3) Potential for bias as developed 
from population with controls from 
private GP or dermatology 
Harbauer 
2003  
(self- 
assessment) 
(39) 
Skin type; UV damage to skin; number of 
naevi 
No AUROC  0.73 
(0.6-0.77) 
  Sens 39 (95% CI 31-
48); Spec 90  
1) Simple 
2) Good discrimination 
1) Would require a computer to 
implement risk model 
2) Potential for bias as developed 
from population with controls from 
private GP or dermatology 
Landi 
2001 (50) 
Presence of dysplastic naevi; skin colour; 
propensity to tan; eye colour 
Yes      1)  Reproducible as relies on 
observation rather than recall 
1) Developed from population with 
most controls friends or family 
members of cases so potential for 
bias 
MacKie 
1989 (51) 
Gender, total number of naevi ≥ 2mm 
diameter; freckling tendency; number of 
clinically atypical naevi ; number of episodes 
of severe sunburn at any time in life 
Yes      1) Relatively simple to use flow 
chart 
1) Potential for recall bias with 
number of episodes of severe 
sunburn at any time in life 
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(a) Uses US Surveillance, Epidemiology and End Results Programme (SEER) and hypothetical cohort rather than testing on this case-control study population 
(b) From validation study in different population to development of the model 
(c) According to the SAMScore, a patient is considered at risk of melanoma if at least one of these 3 criteria is verified: First criterion: Presence of at least 3 risk factors among the 7 following risk factors: 
phototype I or II, freckling tendency, number of melanocytic naevi >20 on both arms, severe sunburn during childhood or teenage years, life in a country at low latitude, a history of previous melanoma, a history 
of melanoma in a first-degree relative Second criterion: A subject under 60 years of age and a number of melanocytic naevi >20 on both arms Third criterion: A subject of 60 years old or over and a freckling 
tendency 
  Components of score Model performance in development population  General comments 
Author Factors included in score 
Physician 
input? 
Discrimination Calibration Accuracy Strengths Weaknesses 
Marrett 
1992 (18) 
Hair colour; skin reaction to repeated sun 
exposure; freckle density; naevus density 
No     Sens 40; Spec 89 1)  Limited opportunity for recall 
bias 
1) Not applicable to patients with 
previous melanoma 
Neilsen 
2011 (16) 
Family history, number of naevi ≥ 3mm on 
left arm, hair colour, time spent on 
sunbathing vacations  
No       1) Developed from population 
based cohort study 
1) Only applies to women  
2) Based on small number of cases 
as relatively short period of follow 
up 
Quereux 
2011 (1) 
(31) 
Sunburn in childhood; family history of 
melanoma; number of naevi on arms; 
density of freckles; skin type; total sun 
exposure 
No AUROC 0.70   Risk cut off 24: 
Sens 60.2 ± 2.8;  
Spec 71.1 ± 1.2 
1) Good discrimination  1) Total sun exposure difficult to 
calculate 
2) Potential for recall bias with 
sunburn in childhood 
Quereux 
2011 (2) 
(31) 
Sex; age; skin type; freckles; number of naevi 
on arms; severe blistering sunburn as a child; 
life in a country at low altitude; melanoma in 
a first degree relative.  
No AUROC 0.73 Hosmer-
Lemeshow 
statistic p = 
0.43 (d) 
Risk cut off 13:  
Sens 64.9 ± 3.4;  
Spec 68.4 ± 1.3 
1) Good discrimination 1) Potential for recall bias with 
sunburn as a child 
Quereux 
2011 (3) 
(31) 
SAMScore (c): phototype I or II; freckling 
tendency; > 20  naevi on both arms; severe 
sunburn during childhood or teenage years; 
life in a country at low altitude; a history of 
previous melanoma; history of melanoma in 
a first-degree relative 
No AUROC 0.71   Sens 63.2 ± 3.6;  
Spec 68.8 ± 1.2 
1) Good discrimination 1) Combinatorial analysis quite 
complicated 
2) Potential for recall bias with 
sunburn as a child 
Weiss  
1990 (52) 
Total number of naevi > 2mm over whole 
body, hair colour, occupational sun exposure 
and skin response to sun 
Yes         1) Unclear description of variables 
included 
Williams 
2011 (34) 
Age; sex; number of severe sunburns aged 2-
18; hair colour age 15; density of freckles on 
arms before aged 20; number of raised 
moles on both arms; prior non-melanoma 
skin cancer 
No AUROC 0.77 
(0.73-0.81) 
AUROC 0.70 
(0.64-0.77) (b) 
  Cut off 25: Sens 61; 
Spec 80 (b) 
Cut off 28: Sens 50; 
Spec 85 (b) 
Cut off 30: Sens 42; 
Spec 90 (b)  
Cut off 34: Sens 29; 
Spec 95 (b) 
1) Good discrimination 
2) Validated on separate group  
3) Only counting raised moles 
distinguishes from freckles 
 
1) Not yet validated for self-
completion 
2) Only applicable ages 35-74 
3) Potential recall bias for number 
of freckles before age 20 
Zaridze 
1992 (53) 
Presence of freckles on arms; number of 
raised moles on arms and moles on body > 
6mm; skin colour; eye colour; frequency of 
sunbathing during lifetime 
No       1) Only counting raised moles 
distinguishes from freckles 
1) Poor description of variables 
included 
2) Potential for recall bias with 
frequency of sunbathing during 
lifetime 
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(d) The Hosmer-Lemeshow statistic assesses whether or not the observed event rates match expected event rates in subgroups of deciles of fitted risk values. A non-significant p value indicates a well calibrated 
model. 
AUROC – area under the receiver operator curve; Sens – sensitivity; Spec – specificity; PPV – positive predictive value; NPV – negative predictive value 
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Table 2. Details of validation studies 
 
Risk 
model 
Study Country, 
Year 
Study 
design 
Data collection 
method 
Selection of cases Selection of 
controls 
Number of 
cases:controls 
(Participation 
rate, %) 
Discrimination Accuracy Utility 
Fortes 
2010 
(33) 
Fortes  
2010        
(33) 
Brazil, 
2005-8 
Case 
Control 
Interview 
administered 
questionnaire and 
examination 
Caucasian individuals 
with histologically 
confirmed primary 
melanoma, > 18 and 
resident in study 
area 
Caucasian patients 
from general wards 
without a personal 
history of skin 
cancer matched by 
age and sex 
64 (97%):         
53 (100%) 
AUROC 0.79 
(0.70-0.86) 
Cut-off level ≥ 3:  
Sens 79.6; Spec 60 
  
Williams 
2011 
(34) 
Williams 
2011       
(34) 
USA, 
1997 
Case 
Control 
(subset 
of 
original 
study) 
Telephone survey Patients with primary 
invasive cutaneous 
melanoma from 
surveillance 
epidemiology and 
cancer register 
Random digit 
dialling 
25% of 
386 (80%): 
727 (63%) (a) 
AUROC 0.70 
(0.64-0.77) 
Cut off 25: Sens 61; Spec 80 
Cut off 28: Sens 50; Spec 85 
Cut off 30: Sens 42; Spec 90 
Cut off 34: Sens 29; Spec 95 
(b) 
  
MacKie 
1989 
(51) 
Jackson 
1998 (54) 
UK, 
1995 
Cohort Self-completion 
of questionnaire 
and  examination 
Consecutive patients > 16 visiting their 
doctor 
388 (26%) (c)     Agreement of self-
report and clinical 
examination: κ 0.43 - 
0.67  
Neilsen 
2011 
(16) 
Westerdalh 
1996 (55) 
Sweden, 
1990-4 
Cohort Postal 
questionnaire 
Random sampling of women who had 
responded to initial questionnaire 1-3 years 
previously 
670 (84%) Test-retest reliability 
of questionnaire: κ 
0.54 – 0.83  
Quereux 
2011  
(1, 2, 3) 
(31) 
Quereux 
2010 (56) 
France, 
2006-7 
Cohort Self-completion 
of questionnaire 
and  examination 
Consecutive patients 18-70 years visiting 
their doctor 
1358 (100%) (d)     Agreement of self-
report and clinical 
examination: % 
correct answers 79.9 
– 98.1 
Quereux 
2011 (3) 
(31) 
Quereux 
2012 (57) 
France, 
2009 
Cohort Self-completion 
of questionnaire 
and examination 
of patients at high 
risk 
Consecutive patients > 18 visiting their
doctor 
1039 (43%) (e) Efficiency 11.54 
(p=0.0016) (f) 
                     
(a) Of 1751 who agreed to take part, 1024 (58%) were subsequently excluded as they were not eligible  
(b) Based on both development and test populations 
(c) The initial response rate to the questionnaire was 66%. Of those who responded, 388 (26%) attended for a skin examination 
(d) Of 1500 patients agreeing to take part,42 (2.8%) were excluded as they were not eligible and  100 (6.7%) for incomplete data 
(e) 7953 completed the questionnaire whilst visiting their GPs. 2404 were high risk and 1039 (43%) of those consulted a dermatologist. Of those 95 had a biopsy and a melanoma was found in 10 
(f) The interpretation of this is that to detect a new case of melanoma it is necessary to screen 11.54 times fewer patients than with non-targeted screening 
 
 
o
n
 June 22, 2014. © 2014 Am
erican Association for Cancer Research. 
cebp.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on June 3, 2014; DO
I: 10.1158/1055-9965.EPI-14-0295 
Table 3. Factors considered and then included in final risk models 
 
 Considered for inclusion in model 
 Included in final risk model 
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Augustsson 1991 (46) † †                                             
Bakos 2013 (30) ‡ ‡                                             
Barbinin 1998 (26)       
Cho 2005 (28)                                               
Dwyer 2004 (27)                                                 
English 1988 (35) ‡ ‡     
Fears 2006 (Female) (47) † n/a                                             
Fears 2006 (Male) (47) † n/a                                             
Fortes 2010 (33) ‡ ‡     
Garbe 1989 (48)                                                 
Garbe 1994 (49) ‡ ‡                                             
Goldberg 2007 (32)       
Guther 2011 (a) (29)                                                
Harbauer 2003 (Physician) (39) † †                                             
Harbauer 2003 (Self) (39) † †     
Landi 2001 (50) † †                                             
MacKie 1989 (51)                                                 
Marrett 1992 (18) † †     
Neilsen 2011 (16)  n/a                                             
Quereux 2011 (Combinatorial analysis) (31)                                                 
Quereux 2011 (OR from regression) (31)       
Quereux 2011 (RR from literature) (31)                                                 
Weiss 1990 (52) † ‡                                             
Williams 2011 (34)                                                 
Zaridze 1992 (53) ‡ ‡                                             
% times included when considered 88 67 0 0 --- 0 50 80 33 59 31 83 80 47 50 0 86 73 50 71 0 67 53 56 
% times included   28 24 0 0 4 0 4 16 24 40 16 20 32 28 32 0 76 44 4 20 0 8 32 20 
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(a) Skin type unclear from methods - use I-VI but no further details     
† Model adjusted for age and/or gender       
‡ Case-control study matched by age and/or gender       
 Did provide results for age stratification in two age ranges 
(b) Computed only for factors considered in more than one model 
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Papers after duplicates removed 
(n = 4141) 
Papers screened 
(n = 4141) 
Papers excluded 
(n = 4080) 
Full-text papers assessed 
for eligibility 
(n = 61) 
Full-text papers excluded, with reasons 
(n = 42) 
 
Does not use stepwise methodology – 19 
Conference abstract – 7 
Not primary research - 6 
Measures of reliability, validity of feasibility of     
   questionnaires not used to develop a model - 3 
Not applicable to general population – 2 
Melanoma not end-point -1 
Duplicate data - 1 
Does not provide multivariate analysis - 1 
Model does not predict melanoma – 1 
Validation of non-stepwise model - 1 
 
Papers included in 
synthesis 
(n = 25) 
MEDLINE 
(n = 2926) 
EMBASE 
(n = 3430) 
Additional papers identified 
through citation searching 
included in synthesis 
(n = 6) 
Risk models included in 
synthesis 
(n = 25) 
Validation papers included 
in synthesis 
(n = 4) 
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